Research and application progress of MGMT promoter methylation in gliomas

O6-methylguanine-DNA methyltransferase (MGMT) is an important DNA repair enzyme. The promoter methylation status of MGMT gene has recently become a biomarker of gliomas. Methylation of the MGMT promoter not only is an important biomarker to evaluate the sensitivity to the chemotherapy with alkylatin...

Full description

Saved in:
Bibliographic Details
Published inChinese Journal of Contemporary Neurology & Neurosurgery Vol. 14; no. 7; pp. 638 - 642
Main Authors Cui-yun, SUN, Shi-zhu, YU
Format Book Review Journal Article
LanguageEnglish
Published Tianjin Shi Tianjin Huanhu Hospital 01.07.2014
Subjects
Biomarkers
CpG islands
Glioma
Methylation
O ⁃methylguanine⁃DNA methyltransferase
Review
Online AccessGet full text

Cover

More Information
Summary:O6-methylguanine-DNA methyltransferase (MGMT) is an important DNA repair enzyme. The promoter methylation status of MGMT gene has recently become a biomarker of gliomas. Methylation of the MGMT promoter not only is an important biomarker to evaluate the sensitivity to the chemotherapy with alkylating agents, but also contributes to predicting prognosis and distinguishing between recurrence and pseudoprogression in glioma patients. Especially in the elderly, MGMT promoter methylation status has recently been introduced to be a biomarker for glioma classification and personalized treatment strategies. This review gives a short summary of the function of MGMT and clinical application of MGMT promoter methylation in personalized treatment strategies, prognosis evaluation and differentiation of recurrence and pseudoprogression of glioma.
ISSN:1672-6731
DOI:10.3969/j.issn.1672-6731.2014.07.017